
    
      Title: Combining 90Y-Ibritumomab tiuxetan (Zevalin) with high-dose chemotherapy of BuCyE and
      autologous stem cell transplantation in patients with relapsed, refractory, or high-risk
      B-cell non-Hodgkin's lymphoma - an open-labeled phase II study.

      Study design: Prospective, multicenter, open-labeled, phase II trial.

      Study objectives:

        -  Primary: event-free survival time following autologous stem cell transplantation with
           90Y-Ibritumomab tiuxetan and BuCyE high-dose chemotherapy in patients with relapsed,
           refractory, or high-risk B-cell non-Hodgkin's lymphoma

        -  Secondary: overall survival response rate toxicity of the treatment combination

      Treatment:

      Z-BuCyE Regimen

        -  Day 21: rituximab, 250 mg/m2, I.V.

        -  Day 14: rituximab, 250 mg/m2, I.V. 90Y-Ibritumomab tiuxetan, 0.4 mCi/kg, I.V.

        -  Day 7, 6, 5: busulfan 3.2 mg/kg I.V.

        -  Day 5, 4: etoposide 200 mg/m2 I.V. every 12 hours

        -  Day 3, 2: Cytoxan 50 mg/kg I.V.

        -  Day 0: autologous stem cell infusion
    
  